{"id":890491,"date":"2025-09-29T16:34:03","date_gmt":"2025-09-29T20:34:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/"},"modified":"2025-09-29T16:34:03","modified_gmt":"2025-09-29T20:34:03","slug":"cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/","title":{"rendered":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">PONTE VEDRA, Fla., Sept.  29, 2025  (GLOBE NEWSWIRE) &#8212; Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.<\/p>\n<p>\n        <strong>Company Webcast<\/strong>\n      <\/p>\n<p>The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zO9Glw4tA3eNI2WILGKJCpsx3Mj1ypdNffap2yJPZjvilNvGeDzYmoXmyGRWbcmE5svAORkegy015lUcXjAWTFmd1pyPpf69O_dPSyfbtC90h6GGdF2QN4GNly5aoZQuxUTIf4xyHvlyKuQ3HoNPmw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/lythampartners.com\/fall2025\/<\/a> or directly at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zO9Glw4tA3eNI2WILGKJCsZJeYKjUQu-KpZiXbO6jEJwGSPnKsgDYZc7JXnKQ63YVWvGGjM-TnYFjHuZb5bqvq4OH-0ofRzbW6rYpAsvpbTwAjTqRnEDqylUAPB5BlfXrV7KWnpJVx41RpW0wwD7Lw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/app.webinar.net\/QG1g6kJWEM0<\/a>. The webcast will also be available for replay following the event.<\/p>\n<p>\n        <strong>1&#215;1 Meetings<\/strong>\n      <\/p>\n<p>Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gMmTj9CTbvcoWnyVg9nf2hNkytBd64Q-YCdTB9a6Sn44GoP9mgzQL5BzNIiv5JwJNszyOWBeekN9nMHos3pOAVxOXIqnS474G2bSE7RFBF4=\" rel=\"nofollow\" target=\"_blank\">1&#215;1@lythampartners.com<\/a> or register for the event at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zO9Glw4tA3eNI2WILGKJCpsx3Mj1ypdNffap2yJPZjuEIOUI_77nXlydOD1rE7pthDZVfjeYiunsYxtSvOBL63lrS2_xVcIebWD6TwmawsbdkhHmjk5_DrQzdrW-uTzwspjVJrjMDSExtgg61EWJ_g==\" rel=\"nofollow\" target=\"_blank\">https:\/\/lythampartners.com\/fall2025invreg\/<\/a>.<\/p>\n<p>\n        <strong>About Cadrenal Therapeutics, Inc.<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XUWtBNjPVwaishCblHCJPHXbCC8wbYEy0txILB3unoKUhjPORZ29Pt2vLW94zna_hjP69eWbY47ZHoNiVT1D6IxTCKtfFMUVRqFTa1COmJjZFCwQAKC4o8S8I8X_O1Kp4MvIrh5tlo3P-IaaJxFFbO5BbhFF05fK92-gf68L2wiJ5kjjqfjXGOM_dAV4NBgTYw8impnTOqwss6UkgRdjmembOQ8G9eIJAU7aSQcrcKubPRzdD6S_Pf4pODMV1YL0T66pU0qVE0PsLZkgUq9qxA==\" rel=\"nofollow\" target=\"_blank\">Cadrenal Therapeutics, Inc.<\/a>\u00a0is a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy. Cadrenal\u2019s lead investigational product is tecarfarin, a novel oral Vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal aims to reduce the clinical complexities of managing Vitamin K antagonists, particularly where direct-acting oral anticoagulants (DOACs) remain inadequate or unproven.<\/p>\n<p>Tecarfarin received Orphan Drug Designation (ODD) and fast-track designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib). The Company also received ODD for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).<\/p>\n<p>For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zO9Glw4tA3eNI2WILGKJCqe2C_Be3k9Xu1TL7-iU48VF6UJZxd7qUW3RGSTZ66VlKtlPPnq5qo85LfTZibKSdik-VQnxK5h0Hr_mW3A7xBfTT2UfqI1jibP-NHr5QDdtLPxvIxDwkcdxLPkGrtVseaYx4UUZqUvCM5GbLZK_f_KDxWwj9yLRSaI1thJ6J6j8o83629dgiMNKmnhEFyHhHwf_qkMjMOT-I8JdpOWh7RElr3lxd6KjOoTLYtxa0-6fr2Su_oIou3jfbKv30XTyFRVRvxgLXuRjACbyUZzvzxTqwEEsaO7F73nExNBQfgg6nziFVPho1iBfuNKMLwHPITJC0JSt_ig6Ot6IYTiUv5RZMK6whkETdmBeXenn4nHRfJBp0H4HScZezdHXJYXUFdqN90zcFtTX6jETw7xG4soak17ZGN_gu7ujLRsfnE0C0sAlbKN8uy8fRkSkCtRjHN10pBf8kimA573vTzqjC4-hqZHIk48uk7F1pgJdE_kU_xeFYiWczguK7yragXThWtvrYgeJ9cAIwd33NjS4JLWa1ELYoe_6Z14fj5DoxgjQLW6ClviJsEgeIQFGrwv-KccBgsw0CNFtwsm6RWxDaVdlWFumDlEPV9RqAYVnVanN\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cadrenal.com\/<\/a>\u00a0and connect with the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pyfH5nSmX1v_8_A0_9IJsIZKaF2ClzvD8ozkbXt5CQs_EQRUve5oca8sB6-guyJqjHZwwno_gjyn7YxSHt6ZYVsFulJDtu1WLdgrYwkrE9_egaBjf_5CLqlKFuqfJJxIwcNAId1Xl6whOSk8nAX3sTM-ctUQqaeAAJQFu38x3MgwmBnuu0s39OtSXIDGR527p85lfentlKiaN7SVUuyEeUrb6kb5_DW-Oi9RmLzcUjkUu802uxwlBsqe72jE9v9X0KDBBnzqkIpqAZmatBlhPFiaJjKHQMEyBooHm1PcbuwZJaKi7T77o5kduTYt_zsOlvW3G6R2eciRlq4OEbQmEMb_pLg9tfPxtYPHjgBTDIpZKD8BCvPBb2D5GLwxU7RPBrQtbDB80TZ55jewZJpn-6x72EqjbLH2KPmKLtAUskOoPLrocq2STD4cbLRmih48X4RmzblQoRhoqWjNx24Xwkqy2B0HhfHu4M56qV-m6MxainF9VodPj9bRVo_6Mk12J-nNbOYMTW0q_3UUb_2__rI0K_PL4tCnNiG9EBT-8wjeoBkKOIUGducsnsMZI4On\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>For more information, please contact:<\/p>\n<p>Cadrenal Therapeutics:<br \/>Matthew Szot, CFO<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6LjUN8HSSWAj1PRrD0fuTuKpbmHepNhrerTQmtsxqeCakkiYkzWJWMqWLqetyIxxjW4T8nOWDlT7gA55nSYoP1mzuw-fVhZYPqtHFwN6mutBKu0m0qm8ZZdo6pGRY-7bVqwlZzbAKHa7PAYhAzGRQFyPZ1o3NBuHz-PYm6ISJabe5nHoGUb4pWcVKEbf6-TqUM24fl_GsuLIWUfS7wnDrho41rR4JcO1zLlIZHKjkh3KeVHmII9W2YVajkSootth3o7diObif52_mxe8hDCpPQ==\" rel=\"nofollow\" target=\"_blank\">press@cadrenal.com<\/a><\/p>\n<p>Investors:<br \/>Lytham Partners, LLC<br \/>Robert Blum, Managing Partner<br \/>602-889-9700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZZEVQU1ir7k4vUzNp3LFBso6OSBEYGeUk67K0ezKMdkBJYnu6s6qxpeSwYKxRIFc1cs_L8jZWbuSB4xl73ptj6usPOwIPETZ5qVTbZQnifrnm1Dr0FIQ7dLp5wjGNugGAtWjZWhxM6XufYzQycwpR64cab0nJWjNTQxfVntdaIzVswKaJB0MiwRpkEncycCNuMYjOVQEwibMR4EZcTsTqQWGBnROYIb8LDSmaCQ6WmKXHpomCVrqR9xv75OZJddkH5Fl5ZvuIsnl5qqtC5rhoCFgfhWimBCOZA1t0MJQ8fc=\" rel=\"nofollow\" target=\"_blank\">CVKD@lythampartners.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YzY4ZThhYWUtNmZkOC00YzE3LWFhMWEtZTVhNzIzOWZmNzhiLTEyNzMzOTktMjAyNS0wOS0yOS1lbg==\/tiny\/Cadrenal-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/fall2025\/ or directly at https:\/\/app.webinar.net\/QG1g6kJWEM0. The webcast will also be available for replay following the event. 1&#215;1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-890491","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/fall2025\/ or directly at https:\/\/app.webinar.net\/QG1g6kJWEM0. The webcast will also be available for replay following the event. 1&#215;1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a &hellip; Continue reading &quot;Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-29T20:34:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025\",\"datePublished\":\"2025-09-29T20:34:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/\"},\"wordCount\":366,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/\",\"name\":\"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\",\"datePublished\":\"2025-09-29T20:34:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk","og_description":"PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) &#8212; Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/fall2025\/ or directly at https:\/\/app.webinar.net\/QG1g6kJWEM0. The webcast will also be available for replay following the event. 1&#215;1 Meetings Management will be participating in virtual one-on-one meetings throughout the event. To arrange a &hellip; Continue reading \"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-29T20:34:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025","datePublished":"2025-09-29T20:34:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/"},"wordCount":366,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/","name":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=","datePublished":"2025-09-29T20:34:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUzNzAzMCM3MTY5ODg0IzIyNjE4NDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2025-investor-conference-on-september-30-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890491","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=890491"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/890491\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=890491"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=890491"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=890491"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}